Lilly wins FDA approval for once-weekly basal insulin Onswik for adults with type 2 diabetes

(AWP Alliance News) - Eli Lilly launched Onswik, an FDA-cleared once-weekly basal insulin for adults with type 2 diabetes, expanding its diabetes franchise into a segment aimed at reducing injection burden versus daily regimens. The approval positions Lilly to compete more directly with established basal insulins from rivals, using dosing convenience as a differentiator in a large and growing insulin market.

Clearance was supported by Phase 3 data in more than 3,400 patients showing comparable A1C lowering versus insulin glargine U-100 or insulin degludec U-100, supporting payer and prescriber confidence in switching. Lilly expects the Onswik KwikPen to reach the U.S. market in the coming months in U-500 and U-1,000 strengths, targeting a wide range of dosing needs.

The product adds another growth lever alongside Lilly's existing diabetes medicines as demand rises for simpler long-term therapy options.

https://www.prnewswire.com/news-releases/us-food-and-drug-administratio…

Disclaimer: This news brief was created using generative artificial intelligence. Eli Lilly and Company published the original content used to generate this news brief via PR Newswire on September 24, 2026, and is solely responsible for the information contained therein.